Climb Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates

Provided By GlobeNewswire – Last update:

Quotes Stocks Mentioned

Article Mentions:

Clinical Trials of Budoprutug in Immune Thrombocytopenia (ITP) and Systemic Lupus Erythematosus (SLE) Underway; 
Trial of Budoprutug in Primary Membranous Nephropathy (pMN) Expected to Initiate in the Coming Weeks

Read more at globenewswire.com